Clinical significance of loss of heterozygosity for M6P/IGF2R in patients with primary hepatocellular carcinoma

AIM：To investigate the relationship between loss of heterozygosity （LOH） for mannose 6-phosphate/insulin- like growth factor 2 receptor （M6P/IGF2R） and the outcomes for primary HCC patients treated with partial hepatectomy. METHODS： The LOH for M6P/IGF2R in primary HCC patients was assessed using six different gene-specific nucleotide polymorphisms. The patients studied were enrolled to undergo partial hepatectomy. RESULTS： M6P/IGF2R was found to be polymorphic in 73.3% （22/30） of the patients, and of these patients, 50.0% （11/22） had tumors showing LOH in M6P/IGF2R. Loss of heterozygosity in M6P/IGF2R was associated with significant reductions in the two year overall survival rate （24.9% vs 65.5%; P = 0.04） and the disease-free survival rate （17.8% vs 59.3%; P = 0.03）. CONCLUSION： These results show M6P/IGF2R LOH predicts poor clinical outcomes in surgically resected primary HCC patients.